Hepatitis B Vaccine
Hepatitis B · Liver cirrhosis · Hepatocellular carcinoma
Hepatitis B is a viral liver infection. In infants and young children, 90% of infections become chronic, leading to cirrhosis and liver cancer decades later. Most adults clear the infection but chronic infection causes 780,000 deaths/year globally.
Overall Benefit Score
Default scenario · 12-month-old · US community (92% vax rate)
Score for your child →For your child's situation, the evidence strongly supports this vaccine. The disease risk is significant and the vaccine provides substantial protection with a well-established safety record.
📊 Evidence Scores
Scores computed from peer-reviewed data using VaxFact's evidence model. Based on default scenario (12-month-old, standard US community).
🦠 Disease Burden
Hepatitis B is a viral liver infection. In infants and young children, 90% of infections become chronic, leading to cirrhosis and liver cancer decades later. Most adults clear the infection but chronic infection causes 780,000 deaths/year globally.
Chronic hepatitis B requires lifelong monitoring and often antiviral medication. Cirrhosis causes fatigue, jaundice, fluid accumulation, and cognitive impairment. Liver cancer has a 5-year survival rate of 15–20%. Patients describe significant anxiety and stigma, with major impacts on employment and relationships.
🛡️ Vaccine Effectiveness
Immunity appears lifelong for most vaccinated individuals. Booster not currently recommended for immunocompetent adults vaccinated as infants. Memory B-cell response persists even when antibody titers wane.
Breakthrough infections extremely rare (<1%). Mostly occur in immunocompromised individuals or those with vaccine non-response (~5% of population).
⚠️ Adverse Events & Side Effects
All probabilities are per 100,000 doses administered, sourced from VAERS, Vaccine Safety Datalink, and post-licensure surveillance studies.
Common Side Effects
Rare Serious Events
📅 Vaccine Schedule
Unvaccinated children and adolescents can receive 3-dose catch-up series at any age. 2-dose adult series (Heplisav-B) available for age 18+.
⚖️ Benefits vs. Considerations
✓ Benefits
- Prevents 3 serious diseases: hepatitis B infection, liver cirrhosis, and hepatocellular carcinoma
- 44 years of post-licensure safety data across >1 billion doses
- Near-complete (98–99%) protection from a disease that is incurable once chronic
- Immunity appears lifelong — only vaccine shown to prevent a human cancer
- Critical for infants born to infected mothers where risk of chronic infection is 90%
- Eliminates need for anxiety about accidental blood exposures throughout child's life
↕ Considerations
- 3-dose series requires multiple healthcare visits over 18 months
- 5% of population are natural non-responders (genetic variation in immune response)
- Injection site reactions common (25% of doses)
- Rare anaphylaxis risk (~1 per million doses) requires 15-minute post-vaccination observation
- Long-term antibody levels wane, though memory protection appears retained
🔬 What Some Researchers Question
These are legitimate scientific debates — not fringe claims. They represent areas of ongoing research or policy disagreement among credentialed experts.
- Some researchers argue newborn vaccination is unnecessary in low-prevalence settings where maternal testing reliably identifies infected mothers (Mitkus et al., 2014 — risk-benefit reanalysis)
- The Recombivax HB and Engerix-B formulations contain aluminum adjuvant; critics argue the safety of neonatal aluminum exposure has been insufficiently studied (Tomljenovic & Shaw, 2011 — disputed by subsequent pharmacokinetic modeling)
- Policy critics note that in low-risk families, perinatal transmission risk is very low and argue that targeted vaccination of at-risk newborns would reduce doses without significant increase in population disease burden
🌫️ Scientific Uncertainties
Honest acknowledgment of what we don't yet know with confidence.
- Exact duration of immunity: studies show >30 years of protection but long-term data still accumulating
- Whether booster doses are needed for immunocompromised children vaccinated in infancy
- Optimal revaccination strategy for the ~5% who don't mount initial antibody response
💉 Related Vaccines
Vaccines often given together or covering related diseases.
🌍 International Policy Comparison
How different countries approach this vaccine — revealing where global consensus is strong vs. where policy diverges.